Riggs Asset Management’s Serina Therapeutics SER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-24
Closed -$148 909
2025
Q2
$148 Hold
24
﹤0.01% 900
2025
Q1
$137 Hold
24
﹤0.01% 625
2024
Q4
$121 Hold
24
﹤0.01% 634
2024
Q3
$161 Hold
24
﹤0.01% 624
2024
Q2
$230 Hold
24
﹤0.01% 628
2024
Q1
$324 Sell
24
-3
-11% -$42 ﹤0.01% 606
2023
Q4
$370 Sell
27
-3
-10% -$55 ﹤0.01% 396
2023
Q3
$721 Hold
30
﹤0.01% 378
2023
Q2
$947 Hold
30
﹤0.01% 348
2023
Q1
$703 Hold
30
﹤0.01% 332
2022
Q4
$585 Hold
30
﹤0.01% 305
2022
Q3
$1K Hold
30
﹤0.01% 317
2022
Q2
$1K Hold
30
﹤0.01% 294
2022
Q1
$1K Sell
30
-3
-9% -$85 ﹤0.01% 310
2021
Q4
$1K Hold
33
﹤0.01% 315
2021
Q3
$1K Hold
33
﹤0.01% 311
2021
Q2
$2K Hold
33
﹤0.01% 299
2021
Q1
$2K Hold
33
﹤0.01% 270
2020
Q4
$2K Hold
33
﹤0.01% 257
2020
Q3
$0 Hold
33
﹤0.01% 285
2020
Q2
$1K Hold
33
﹤0.01% 243
2020
Q1
$1K Hold
33
﹤0.01% 246
2019
Q4
$2K Hold
33
﹤0.01% 271
2019
Q3
$2K Hold
33
﹤0.01% 230
2019
Q2
$4K Hold
33
﹤0.01% 222
2019
Q1
$4K Hold
33
﹤0.01% 210
2018
Q4
$3K Buy
+33
New +$4.2K ﹤0.01% 208

Other funds holding SER

Riggs Asset Management's SER Position: Q3 2025 in Review

Riggs Asset Management sold out of Serina Therapeutics (SER) in Q3 2025, closing a stake of 24 shares — an estimated $148 sold.

Riggs Asset Management first reported a position in SER in Q4 2018 and held it in 27 quarters. The position peaked at $4K in Q2 2019. 25 funds tracked by Wall St. Rank hold SER as of Q3 2025.

  • Riggs Asset Management reported no remaining Serina Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 24 Serina Therapeutics shares in Q3 2025, an estimated $148.
  • Riggs Asset Management first reported a position in Serina Therapeutics in Q4 2018 and held it in 27 quarters.
  • Riggs Asset Management's Serina Therapeutics position peaked at $4K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.